EU reviewing Pfizer's COVID antiviral pill for emergency use

The European Union’s drug regulator says it's started evaluating the coronavirus pill made by Pfizer Inc. to see if it might be used in emergency situations before it's officially authorized

Via AP news wire
Friday 19 November 2021 15:45

The European Union's drug regulator said it has started evaluating the coronavirus pill made by Pfizer Inc. to see if it might be used in emergency situations before it is officially authorized.

In a statement Friday, the European Medicines Agency said it is looking at data on the effectiveness of Pfizer's antiviral pill when given to people infected with COVID-19 who are not yet hospitalized but are at risk of developing severe disease.

Early results suggest Pfizer's pill reduces the risk of hospitalization or death, compared with people who received a dummy pill, when they were treated within three to five days of developing COVID-19 symptoms, the agency said.

Although a more comprehensive evaluation will likely start soon, “this current review will provide EU-wide recommendations in the shortest possible timeframe so they can be used by national authorities who wish to take evidence-based decisions on the early use of the medicine,” the regulator said.

Europe is the epicenter of the COVID-19 pandemic, with numerous countries facing surges of disease amid lagging vaccination rates. On Friday, Austrian Chancellor Alexander Schallenberg announced the country would go into a national lockdown and that COVID-19 vaccinations would be mandatory by next year.

Pfizer said earlier this month that its pill cut the risk of hospitalization or death by up to 90%. The company reported few details on side effects but said rates of problems were similar between the groups at about 20%.

An independent group of medical experts monitoring the trial recommended stopping it early, standard procedure when interim results show such a clear benefit. The data has not yet been published for outside review, the normal process for vetting new medical research.

Most COVID-19 treatments require an IV or injection. Competitor Merck’s COVID-19 pill has already been authorized by Britain and Pfizer's pill is under consideration by the U.S. Food and Drug Administration.

Since the beginning of the pandemic last year, researchers worldwide have been racing to find a pill to treat COVID-19 that can be taken at home to ease symptoms, speed recovery and keep people out of the hospital.

___

Follow AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in